ATNM
Price
$1.59Alerts
Change
+$0.02 (+1.27%)
Updated
Nov 11, 04:59 PM (EDT)
Capitalization
44.96M
One day until earnings call
Intraday BUY SELL Signals
MGX
Price
$0.76Alerts
Change
+$0.06 (+8.57%)
Updated
Nov 11 closing price
Capitalization
26.8M
Intraday BUY SELL Signals
Interact to see
Advertisement

ATNM vs MGX

ATNM vs MGX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ATNM vs. MGX commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATNM is a Hold and MGX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ATNM with price predictions
Nov 11, 2026

ATNM in upward trend: price rose above 50-day moving average on October 16, 2026

ATNM moved above its 50-day moving average on October 16, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on ATNM as a result. In 74 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for ATNM just turned positive on November 10, 2026. Looking at past instances where ATNM's MACD turned positive, the stock continued to rise in 37 of 50 cases over the following month. The odds of a continued upward trend are 74%.

The 10-day moving average for ATNM crossed bullishly above the 50-day moving average on October 20, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 67%.

The 50-day moving average for ATNM moved above the 200-day moving average on October 20, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +3.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where ATNM advanced for three days, in 168 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.

Bearish Trend Analysis

The 10-day RSI Indicator for ATNM moved out of overbought territory on October 26, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In 19 of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at 86%.

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATNM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.

ATNM broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for ATNM entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 22 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. ATNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.484) is normal, around the industry mean (3.498). P/E Ratio (4.086) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1.105) is also within normal values, averaging (440.869).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for MGX with price predictions
Nov 11, 2026

MGX in -10.20% downward trend, declining for three consecutive days on November 06, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where MGX declined for three days, in 157 of 179 cases, the price declined further within the following month. The odds of a continued downward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for MGX entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MGX's RSI Indicator exited the oversold zone, 18 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 21 of 30 cases where MGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.

The Moving Average Convergence Divergence (MACD) for MGX just turned positive on October 29, 2026. Looking at past instances where MGX's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.

Following a +4.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where MGX advanced for three days, in 88 of 111 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

MGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.238) is normal, around the industry mean (3.498). P/E Ratio (-0.285) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.195) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. MGX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MGX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
ATNM: Fundamental Ratings
ATNM
OUTLOOK RATING
1..100
43
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
22
PRICE GROWTH RATING
1..100
35
P/E GROWTH RATING
1..100
8
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATNMMGX
RSI
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
70%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
69%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 9 days ago
87%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
68%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (ATNM: $1.59 vs. MGX: $0.76)
Brand notoriety: ATNM and MGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATNM: 58% vs. MGX: 365%
Market capitalization -- ATNM: $44.96M vs. MGX: $26.8M
ATNM [@Biotechnology] is valued at $44.96M. MGX’s [@Biotechnology] market capitalization is $26.8M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATNM’s FA Score shows that 2 FA rating(s) are green while MGX’s FA Score has 1 green FA rating(s).

  • ATNM’s FA Score: 2 green, 3 red.
  • MGX’s FA Score: 1 green, 4 red.
According to our system of comparison, ATNM is a better buy in the long-term than MGX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATNM’s TA Score shows that 6 TA indicator(s) are bullish while MGX’s TA Score has 5 bullish TA indicator(s).

  • ATNM’s TA Score: 6 bullish, 5 bearish.
  • MGX’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, MGX is a better buy in the short-term than ATNM.

Price Growth

ATNM (@Biotechnology) experienced а +12.77% price change this week, while MGX (@Biotechnology) price change was -4.27% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.

Reported Earning Dates

ATNM is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-0.49% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

ATNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATNM has been loosely correlated with PDSB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ATNM jumps, then PDSB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATNM
1D Price
Change %
ATNM100%
+1.27%
PDSB - ATNM
35%
Loosely correlated
-0.97%
WVE - ATNM
34%
Loosely correlated
+0.29%
CRBU - ATNM
33%
Loosely correlated
-4.80%
MGX - ATNM
33%
Poorly correlated
+8.04%
AMLX - ATNM
32%
Poorly correlated
+2.88%
More

MGX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MGX has been loosely correlated with EDIT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MGX jumps, then EDIT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MGX
1D Price
Change %
MGX100%
+8.04%
EDIT - MGX
47%
Loosely correlated
-4.99%
VYGR - MGX
44%
Loosely correlated
-3.56%
BCYC - MGX
44%
Loosely correlated
N/A
SANA - MGX
44%
Loosely correlated
-5.76%
RCKT - MGX
43%
Loosely correlated
+1.22%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SNTH29.260.29
+1.00%
MRP Synthequity ETF
DTEC50.790.44
+0.87%
ALPS Disruptive Technologies ETF (DTEC)
DLS85.240.52
+0.61%
WisdomTree International SmallCap Dividend Fund (DLS)
EMFI48.03N/A
N/A
Pictet Emerging Markets Debt ETF (EMFI)
CSTE1.28-0.08
-5.88%
Caesarstone Ltd